Managing multiple myeloma in elderly patients
Authors:
- 28 August 2017
- journal article
- other
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (6) , 1300-1311
Abstract
Multiple myeloma (MM) is a plasma cell neoplasm that affects elderly individuals with two-thirds of patients over 65 years at diagnosis. However, data available are derived from clinical trials conducted in younger patients. Fewer studies investigated treatment options in the elderly. This review summarizes the clinical outcomes and toxicities associated with therapeutic regimens in older patients including doublet, triplet and high dose therapyin newly diagnosed patients and relapsed patients with MM. We highlight the importance of an approach tailored to individuals, incorporates the geriatric frailty assessment, considers comorbiditiess and commits to early recognition and management of toxicities ranging from myelosuppression to polypharmacy. To date, no trial has prospectively investigated a tailored treatment paradigm in older patients based on frailty and/or comorbidities. As the population ages, the proportion of MM patients with advanced age will grow. Studies are indicated to determine optimal treatment approaches in this increasingly heterogeneous geriatric population.Keywords
Funding Information
- P30 (CA008748)
This publication has 75 references indexed in Scilit:
- Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scoresHaematologica, 2016
- Treatment for patients with newly diagnosed multiple myeloma in 2015Blood Reviews, 2015
- Frontline therapy of multiple myelomaBlood, 2015
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood, 2015
- Frailty in elderly peopleThe Lancet, 2013
- Drug Policy for an Aging Population — The European Medicines Agency's Geriatric Medicines StrategyNew England Journal of Medicine, 2012
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood, 2010
- Hematopoietic stem cell transplantation for multiple myeloma beyond 2010Blood, 2010
- Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trialThe Lancet, 2007
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialBlood, 2004